Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL versus MD 76R.
IOPAMIDOL vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble radiographic contrast agent that attenuates X-rays by increasing the density of vascular structures and organs, thereby enhancing contrast in imaging studies. It does not have a pharmacological mechanism of action but exerts its effect via physical radiopacity.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., cerebral angiography: 5-10 mL; coronary arteriography: 3-10 mL per injection; CT: 50-150 mL; adults: up to 200 mL total).
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Clinical Note
moderateIopamidol + Metformin
"The risk or severity of adverse effects can be increased when Iopamidol is combined with Metformin."
2 hours; prolonged in renal impairment (up to 30 hours in anuria)
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal: >90% unchanged; biliary/fecal: <2%
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent